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Calpain Activity in Patients With Thrombotic Thrombocytopenic Purpura Is Associated With Platelet Microparticles
By John G. Kelton, Theodore E. Warkentin, Catherine P.M. Hayward, William G. Murphy , and Jane C. Moore
Thrombotic thrombocytopenic purpura (lTP) is characterized by thrombocytopenia and disseminated platelet thrombi throughout the microvasculature. Studies by our group have demonstrated calcium-dependent proteolytic activity (calpain) that is no longer detectable in the serum of patients with acute TTP after their recovery. The purpose of this study was t o investigate if the protease activity of TTP was detectable in plasma and, therefore, not an in vitro phenomenon secondary t o the formation of serum. Additionally, we looked for evidence of membrane association of the active protease in the patients' samples, which would explain the persistence of its activity in the presence of plasma inhibitors. Acute TTP samples, both serum and plasma, were collected from 10 patients with TTP. Calpain was measured using bioassays for enzyme activity and also by detection of the protein using immunoblotting with an anticalpain monoclonal antibody (MoAb). In all instances, calpain could be detected both functionally and antigenically in the acute TTP HROMBOTIC thrombocytopenic purpura (TTP) is a T potentially life-threatening illness that is characterized by destructive thrombocytopenia and schistocytic hemolytic anemia. Some patients also have ischemic neurologic events, fever, and renal failure.' The cause of the illness remains debated, but for many years investigators have postulated that a platelet-aggregating factor could participate in the pathogenesis of the disorder. Two groups of investigators have described different platelet-aggregating factors using plasma or serum from patients with TTP.2,3 Our group has reported that patients with 'ITP have calpain (calcium-dependent protease) activity in their serum. 4 In vitro and in vivo observations have led us to postulate that this unregulated calpain activity contributes to the pathogenesis of the disease. Calpain is an intracellular enzyme found normally in many tissues including platelet^.^ Calpain activity is neutralized by several plasma inhibitors including high molecular weight kininogen? Hence, our model of TTP requires an sera and plasma. No calpain activity could be detected in any of the controls, although antigenic calpain was detectable in one sample from a patient who had undergone cardiopulmonary bypass surgery. To investigate whether the calpain was associated with microparticles in the plasma, the 'ITP plasma samples were ultrafiltered and ultracentrifuged. Activity was not lost by passage across a 0.2-pm filter but was detectable only in the pellet following ultracentrifugation. Membrane association of the calpain in the microparticles also was demonstrated using solubilization with Triton X-100. Immunoprecipitation studies demonstrated that the calpain activity could be removed by MoAbs against platelet membrane glycoproteins (IX and Ilb/llla) but not by a MoAb against red blood cell membrane glycophorin. These studies indicate that active calpain is associated with platelet microparticles in plasma from patients with TTP.
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explanation of how calpain can be active in the plasma environment in TTP patients. One potential explanation would be for the calpain to be bound to particles in the plasma. Other investigators have shown that membranebound calpain is protected from inhibition.' In this report, we describe studies investigating if calpain is present in the soluble fraction or particulate fraction of TTP plasma. Using ultracentrifugation, ultrafiltration, immunoprecipitation, and solubilization by detergents, we found that the calpain activity observed in patients with TTP was associated with platelet microparticles in the plasma.
MATERIALS AND METHODS
All reagents were obtained from Sigma Chemical Co (St Louis, MO), except where otherwise stated.
Patient samples. Blood was collected from 10 patients with l T P before the patients had received any treatment. All patients had thrombocytopenia and schistocytic hemolytic anemia, and some also had neurologic events. All other causes of thrombocytopenia and schistocytic hemolytic anemia (such as disseminated intravascular coagulation) were excluded. All patients were treated with either plasma exchange or plasma infusion.
Serum and plasma samples were collected from each patient. The serum was allowed to clot at room temperature. The samples were centrifuged, the serum removed and frozen at -70°C until tested. Immediately before testing, the samples were thawed in a 37°C water bath. The plasma was collected into acid-citratedextrose (ACD) either with or without protease inhibitors that included phenylmethylsulphonyl fluoride (PMSF), 1 mmol/L; D-phenylanyl-1-propyl-I-arginine chlormethyl ketone (PPAC) (Calbiochem-Behring Corp, La Jolla, CA), l pmol/L; aprotinin, 100 KIU; EDTA, 5 mmol/L; and leupeptin, 1 pmol/L.8 Control samples were obtained from healthy normal donors. Samples were also collected from five patients immediately following cardiopulmonary bypass surgery (CPB). These patients have platelet microparticles in their plasma but show no laboratory evidence of TTP?
The study was permitted by the University Approved Ethics Review Committee. 
Associated With Platelet Microparticles
Five milliliters of TTP patient serum, TTP plasma with inhibitors, control serum, control plasma, and purified calpain (15 pg) were ultracentrifuged (30,OOOg for 30 minutes at 4°C). The supernatant fluid was removed. and the pellets were resuspended in 1 mL of calcium and albumin-free Tyrode's buffer. Calpain was measured functionally and antigenically in the supernatant fluids and resuspended pellets. The calpain used as a positive control was purified from pooled platelets from normal donors using precipitation and chromatography.1° The calpain appeared as a single band at 80 Kd using Coomassie Blue staining of the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and had approximately 9,000 U/mg of functional casein lysis activity.
To characterize the size of the particles and to ensure that there were no extraneous cells present after the initial centrifugation, plasma from three TTP patients and three normal controls were further processed using a 0.45-pm filter followed by a 0.2 pm filter (Acrodisc, Gelman Sciences, Ann Arbor, MI). The filtered plasma samples were then used in the centrifugation studies.
TTP and control plasma samples were centrifuged (30,000g for 30 minutes at 4°C) and the pellets mixed with 2 mL of 1% Triton X-100 or buffer control for 10 minutes at 22°C. Biobeads (Biorad Labs Ltd, Mississauga, Ontario, Canada) were used to remove the residual Triton. The samples were centrifuged (30,000g for 30 minutes at 4"C), the supernatant fluid was removed and tested for calpain activity.
Immunodepletion studies. Cyanogen bromide-activated Sepharose CL4B (CNBr) beads (Pharmacia Fine Chemicals, Baid'Urfe, Quebec, Canada) were prepared according to the manufacturer's instructions. The beads were divided into 5-mL aliquots, and separate samples of beads were coupled with 1 mg monoclonal antibodies (MoAbs) against platelet glycoproteins IX (Beb-1)" and IIb/IIIa (Raj-1),12 glycophorin (AMAC Inc, Westbrook, ME), calpain, or polyclonal antibodies against mouse IgG (Jackson Labs, BioCan, Mississauga, Ontario, Canada) or buffer. The monoclonal anticalpain (B27D8)I3 was a gift from Dr J. E k e (Queen's University, Kingston, Ontario, Canada). The resuspended pellet prepared from 30 mL TTP patient plasma (with inhibitors) or purified calpain (50 pg) was added to 0.5 mL of the beads coupled with anti-IIb/IIla, anti-IX, or anti-glycophorin and incubated at 4°C overnight. The mixture was centrifuged (12,000g for 2 minutes), and the supernatant fluid was removed. The beads were resuspended in 1.0 mL of 0.015 mol/L Tris-HCI with 0.15-m sodium chloride (Tris/NaCl), pH 8.0, and the beads were washed five times using the Tris/NaCI and eluted with 0.2 mL of 2% SDS containing 2% Triton X-100 (Pierce Chemical Co, Rockford, IL). The eluate was diluted to 1 mL with Tris/NaCl, and any eluted MoAb was absorbed out using 0.5 mL of the antimouse IgG beads. The eluates were then incubated with 0.5 mL anticalpain CNBr beads at 4°C overnight. Following the incubation, the beads were washed five times and prepared for SDS-PAGE by boiling for 3 minutes in 100 p L of SDS sample buffer containing 5% 2-mercaptoethanol. After centrifuging for 3 minutes at 12,00Og, 80 pL of the supernatant were applied to 10% SDS-PAGE followed by transblotting. The blots were then reacted with lZI anticalpain radiolabeled with sodium iodide (Na lZ5I) (Amersham, Arlington Heights, IL) by the chloramine-T method. In parallel studies, plasma (3 mL) from patients with TTP or purified calpain (50 pg) was added to 1 mL of each of the MoAb beads and incubated at 4°C overnight.
Centrifugation studies.
Ultrafiltration studies.
Solubilization with detergents.
The mixture was centrifuged (12,000g for 2 minutes) and the supernatant fluid was removed. The beads were washed five times and eluted with 0.1 mol/Lglycine, pH 2.8. The pH was immediately adjusted to 7.4 and the eluate was tested for calpain activity.
Plasma samples (50 pL) from five TTP patients and a normal control and purified calpain (5 pg) were incubated with normal plasma or total kininogen-deficient plasma (25 pL), (George King Bio-Medical Inc, Overland Park, KS) with added hirudin (5 U/mL). After 60 minutes at 2TC, these samples were tested in the 14C-serotonin release assay.
Inhibition studies.
Functional Measurement of Calpain
Two different functional assays were used to measure calpain activity in the serum and plasma from patients with TTP, the Casein Lysis AssayI3 and the 14C-Serotonin Release Assay.14 To ensure that the calpain activity was not an in vitro phenomenon related to clot formation, hirudin (5 U/mL final) was added to five TTP and five normal plasma samples that were collected into ACD without inhibitors. Both serum and plasma samples were tested using the functional assays to discern any in vitro generation of proteolytic activity.
Calpain was functionally quantitated by measuring Ca2+-dependent hydrolysis of casein. In brief, 200 pL of casein (10 mg/mL), 90 pL 50 mmol/LTris HCI (pH 7.8), 5 mmol/L CaC12, and 100 p L sample were incubated for 20 minutes at room temperature. The reactions were stopped with 0.3 mL of ice-cold 10% trichloracetic acid. A unit of activity was defined as an increase of 0.1 A280 unit in the acid supernatant: the specific activity of calpain was approximately, 9,000 U/mg.
The ability of sera and plasma from patients with TTP to release 14C-serotonin (Amersham Corp, Oakville, Ontario, Canada) from normal platelets was tested as described.l4 Platelets from healthy donors were radiolabeled with 14C-serotonin (1.67 x pCi/106 platelets), and 60 pL of the labeled platelets (600 x 109/L) were mixed with 20 pL of the test samples. After a 30-minute incubation at room temperature, the reaction was stopped by the addition of 100 pL of 10 mmol/L EDTA, and the 14C-serotonin released into the supernatant was measured? Parallel studies were performed with added leupeptin (1 pmol/L) and N-[N-(L-3-trans-carboxyoxiran-2-carbonyl)-Lleucyl]-agmatin (E64, 5 pmol/L) (Boehringer Mannheim, Germany) to confirm that the serotonin release was calpain mediated. Unbound leupeptin and E64 was removed by extensive dialysis (24 hours at 4°C) in Tris saline. Leupeptin is a reversible inhibitor of serine and thiol proteases. E-64 is an irreversible inhibitor of thiol proteases.
The pellets harvested from ultracentrifuging plasma were probed for calpain using an MoAb that reacts with transblotted calpain. The MoAb reacts with the 80-Kd band of ~a1pain.l~ The pellets harvested from 5 mL of the plasma (with inhibitors) were resuspended in 1 mL Tris saline and 10 p L were applied to a 5% to 15% SDS-PAGE under reduced conditions. Prestained reference molecular weight proteins were run in parallel and included myosin (225 Kd), phosphorylase B (109.1 Kd), bovine serum albumin (BSA) (71.8 Kd), ovalbumin (45.8 Kd), carbonic anhydrase (28.5 Kd), and P-lactoglobulin (18.4 Kd) (Bethesda Research Laboratories, MD). Dilutions of purified calpain (2.5 to 20 pg) were also applied to the gel to assess the sensitivity of the detection system. Following electrophoresis, the proteins were transblotted onto nitrocellulose. The nitrocellulose was washed, blocked with 5% BSA and reacted with monoclonal 1251-anticalpain (1/1,000 dilution).
Casein lysis assay.
''C-serotonin release.
Antigenic detection of calpain.
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RESULTS

Association of Calpain Activity With Platelet Micro particles
When TTP serum or plasma samples were tested after ultracentrifugation, calpain was not detectable in the supernatant tested either functionally or antigenically (Table 1) . Calpain was detectable in the resuspended pellet functionally (Casein lysis assay and *4C-serotonin release assay) and antigenically, using immunoblotting with the MoAb. The calpain activity in the pellet was inhibited by the thiol protease inhibitors leupeptin and E-64.
Ultrafiltration of the plasma before high-speed centrifugation did not remove the calpain activity, indicating that the calpain was associated with particles less than 0.2 p in size.
When the plasma from TTP patients was incubated with Sepharose beads coupled with MoAbs against two different platelet glycoproteins (glycoproteins IX and IIb/IIIa), the calpain activity could be recovered from the beads. The activity could also be recovered using anticalpain beads. In contrast, treatment of the TTP samples with antiglycophorin beads or control beads did not result in recoverable calpain activity. Purified calpain was not recovered using Some of the samples also were tested after ultracentrifugation and separation of the various fractions. The results are given as percent 14C-Serotonin released compared with the total amount of 14C-Serotonin contained in the test volume of platelets. All plasma samples have hirudin (5 U/mL) added. Plasma samples (with inhibitors) from five different l T P patients are shown along the left side of the table. The samples were incubated with cyanogen bromide-activated Sepharose CL-4B beads linked with the various MoAb shown across the top of the table. After absorption, the beads were eluted and the activity tested in the serotonin release assay. Positive results were only observed when immunoprecipitation and elution were performed using beads linked with MoAbs against platelet proteins. The results are expressed as percent 14C-serotonin released compared with the total amount of 14C-serotonin contained in the test volume of platelets.
anti-IIb/IIIa beads, anti-IX beads, antiglycophorin beads, or control beads. The anticalpain beads recovered the calpain activity ( Table 2) . Immunoblotting confirmed the presence of calpain in the TTP plasma pellet eluates from the anti-IX and anti-IIb/IIIa beads. No calpain was detected antigenically using the antiglycophorin beads (Fig l) .
Following treatment with Triton X-100, the pellets were recentrifuged and the supernatants were tested for calpain activity. Without adding Triton, there was no activity in the supernatants. However, calpain activity could be detected in the supernatants from the Triton-treated TTP pellets. Purified calpain had 86% activity without Triton and 63% after Triton treatment. All controls were negative before and after treatment with Triton (Table 3) .
The normal plasma and the total kininogen-deficient plasma showed no significant inhibition of the TTP plasma activity. The purified calpain activity was inhibited by the normal plasma, and some inhibitory activity was still present in the kininogen-deficient plasma (Table 4) .
Functional Activity of Calpain
The pellets harvested from the plasma samples from all 10 patients with TTP had calpain activity as measured by their ability to hydrolyse casein (1.2 to 5.9 U/mL). The addition of leupeptin to the samples before testing prevented casein lysis. The normal controls and the CPB samples had no calpain activity as measured in this assay (0.4 to 0.7 U/mL). Purified calpain (15 pg) had 2.7 U of activity (Table 5) .
Calpain activity was also detected using the 14C-serotonin release assay. Serum from each of the patients with TTP caused serotonin release from normal 14C-serotoninlabeled platelets. No calpain activity was detected in any of the controls (Table 1 ). The addition of leupeptin or E-64 inhibited the calpain-dependent release of serotonin. Five TTP plasma and five normal plasma samples with added hirudin were tested in the IJC-scrotonin release assay. Comparable calpain activity was observed using either sera or plasma. This result indicated that thc calpain was active in plasma and was not generated during clotting ( Table 1) .
Antigenic Detection of Calpain
Calpain was detected antigenically in the pellets harvested after ultracentrifugation of the TTP plasma samples collected into inhibitors. The calpain was identified using the MoAb. Antigenic calpain was detected in the plasma pellet from one of the CPR patients; however, no functional Plasma pellets were resuspended in Tyrode's buffer with and without Triton X-100. followed by removal of the Triton X-100 and a repeat ultracentrifugation. Supernatants were collected and tested for functional calpain activity in the 14C-serotonin release assay. The results are expressed as percent I4C-serotonin released compared with the total amount of W-serotonin present in the test volume of platelets.
calpain activity was associated with this sample. Using the MoAb, reactive bands were noted at 80 Kd (the inactive calpain form) and 78 Kd (the activated-calpain form)" in each of the TTP samples (Fig 2) . Using diluted purified calpain we demonstrated that the detection system was sensitive to concentrations of calpain as low as 2.5 pg.
DISCUSSION
TTP is characterized by disseminated platelet thrombi throughout the microcirculation of the body. These platelet TTP plasma pellets, a normal plasma pellet, and purified calpain were preincubated with kininogen-deficient plasma, normal plasma, or buffer and then tested in the 14C-Serotonin release assay. Before ultracentrifugation, the test samples were collected into reversible calpain inhibitors. The TTP plasma pellets activity was not inhibited by the plasma but the purified calpain activity was. The results are expressed as percent '%-serotonin released.
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The plasma pellets harvested from l T P patient plasma, normal plasma, and CPB patient plasma were resuspended in Tris saline and tested in the casein lysis assay. All plasma samples were collected into inhibitors. Only the pellets from the l T P patients and the purified calpain resulted in casein lysis. This activity was inhibited by leupeptin thrombi contribute to thc thrombocytopenia that charactcrizcs this disorder. Thrombi that obstruct blood vessels producc the strokcs, cardiac arrests, and othcr ischcmic cvcnts that can be obscrvcd in TTP.' Thcsc clinical obscrva-A 1 2 3 4 5 6 7 8 tions havc led rcscarchcrs to look for an in vivo platelctaggregating factor that could contribute to the pathophysiology of thc discase. 2.3 Moakc ct al proposcd that von Willcbrand factor (vWF) participates in thc pathogcnesis of TTP as cvidenccd by abnormalities of vWF in patients with both acquircd and famllial ?TP.I5 Subscqucntly, wc obscrved similar abnormalitics of vWF and dcmonstratcd that the platclct-aggregating activity prcscnt in I T P scrum was a calcium-dcpcndcnt protease (calpain).3.J Further studics dcmonstratcd that calpain can modify the vWF, making it intensely platclct rcactivc.I7 Calpain is a cytosolic enzyme found in platclcts as wcll as many othcr cclls5 and has scvcral natural inhibitors, including high molecular weight kininogen." Conscqucntly, this modcl of TTP rcquircs an cxplanation of how calpain ovcrcomcs thc plasma inhibitors.
Rcccnt studics by othcr invcstigators have offcrcd onc possiblc cxplanation. Calpain can bccomc mcmbranc associatcd in thc prcscnce of calcium.1x Whcn calpain is bound to a mcmbranc, it is active but more difficult to inhibit.7 For this rcason, wc investigated whcthcr the ITP-associated calpain activity might bc bound to microparticlcs.
Thc first stcp was to confirm that calpain was present both functionally and antigcnically in plasma from patients with ITP. In all of our prcvious studies, calpain activity was measured using paticnt scrum, raising thc possibility of an in vitro phenomenon. In the present study, plasma samples werc collcctcd into ACD with and without rcversible inhibitors added to prcvcnt in vitro protcasc activity. In all of the acutc TTP plasma samples, calpain was dctcctcd functionally (1.2 to 5.9 cascinolytic U/mL) and antigenically.
In thc next scrics of studies we invcstigatcd the location of thc calpain in thc plasma. We found that whcn TTP serum or plasma was ultracentrifuged, calpain. measured antigenically or functionally, could no longer bc dctcctcd in the supernatant but was found in thc pcllct. Ultrafiltering thc samplcs bcforc ultraccntrifugation did not altcr thc use only.
For personal at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From calpain activity, thereby showing that the calpain detected in the pellet was associated with microparticles less than 0.2 pm in size and not associated with any residual cells present after the initial centrifugation. Further evidence of the membrane association of the calpain activity came from the studies using a detergent. The pretreatment of the TTP plasma pellets with detergent resulted in the loss of the ability to isolate the calpain activity by centrifugation. Purified calpain was inhibited by normal plasma but only slightly with kininogen-deficient plasma. The slight inhibition with kininogen-deficieht plasma may have been caused by secondary calpain inhibitors found in plasma, such as 012 macroglobulin.6 However, TTP-associated calpain activity was not inhibited by either normal plasma or kininogendeficient plasma. This suggests that membrane-associated calpain may be protected from inhibition.
In the final series of studies, we characterized the microparticles that carried the calpain activity. Using MoAbs linked to activated Sepharose beads, we demonstrated that antibodies against platelet glycoproteins IX and IIb/IIIa were capable of immunoprecipitating the microparticles and depleting the calpain activity. An MoAb against the red blood cell (RBC) membrane component, glycophorin, had no effect.
The studies described in this report demonstrate that calpain is present on platelet microparticles in plasma and sera from patients with TTP and is resistant to inhibition by the cysteine protease inhibitors in normal plasma. Although the association between calpain and the disease activity in TTP may be a causal one, a collateral association remains a possibility.
